Curaleaf Holdings reported first quarter 2026 revenue of $324 million, a 6% increase year-over-year, driven by 2% domestic and 35% international growth. The company achieved a gross profit margin of 49% and net income of $70 million, reflecting strong operational performance despite some margin pressure. Curaleaf expanded its retail footprint in key U.S. states and completed the full acquisition of its German subsidiary, Four 20 Pharma. The company also filed for DEA registration, positioning itself for growth following recent regulatory changes in medical cannabis. Curaleaf's strategic investments and new product launches support its outlook for continued industry leadership.
Morpho Association secured $175 million from investors including Paradigm and a16z to develop an open credit network that bridges traditional financial systems with blockchain-based capital markets. This funding highlights growing investor interest i...
The Invesco Solar ETF (TAN) has been downgraded from a buy to a hold rating due to less attractive valuation and weakening technical indicators. Despite solid long-term earnings growth, the fund faces challenges from lower oil prices, weak share-pric...
Securitize, backed by BlackRock, has tokenized $295 million of its NYSE-listed stock on the Solana blockchain during its IPO, marking a major step in merging traditional equity markets with blockchain technology. This move enhances Solana's credibili...
The Taiwan Freedom Project has released a special 32-page section in The Washington Times titled "Why Taiwan Matters, Now More Than Ever," emphasizing Taiwan's critical geopolitical role and the threats it faces from China. The publication features b...
Bitcoin's realized profit and loss ratio among short-term holders has dropped to its lowest point in 43 months, with nearly half of its supply underwater, a pattern seen at previous cycle bottoms in 2012, 2014, 2019, and 2022. This capitulation phase...
